Top Industry Leaders in the Onychomycosis Market
Latest Onychomycosis Companies Update
-
Apr 2023: Leading pharmaceutical company Cipla said it has signed a license agreement with Novartis Pharma AG to produce and distribute the Galvus brand, used to treat type 2 diabetes, starting January 1, 2026. According to a regulatory filing, the Mumbai-based business and Novartis Pharma AG have inked a permanent license deal for producing and marketing the Galvus and Galvus combo brands. According to the pharmaceutical company, Galvus is one of the top brands in the Dipeptidyl Peptidase-4 (DPP4) market and a well-known brand in the oral diabetes medicine sector.
-
Aug 2023: Today, its strategic partner, Kaken Pharmaceutical Co. Ltd., launched NexoBrid® in Japan to manage deep partial and full-thickness burns in adults and pediatric patients. MediWound Ltd. is a fully integrated biopharmaceutical business dedicated to developing next-generation enzymatic therapeutics for tissue repair. The exclusive rights to market and dispense NexoBrid in Japan belong to Kaken Pharmaceutical, a well-regarded pharmaceutical firm in Japan. For handling deep partial and full-thickness thermal burns, NexoBrid is recommended for eschar eradication. The present standard of care is based mostly on costly, non-selective surgical excisions that may result in deformity.
List of Onychomycosis Key companies in the market
- Novartis AG (Switzerland)
- Pfizer, Inc. (the US)
- Galderma Laboratories (Switzerland)
- Bausch Health Sciences (Canada)
- Moberg Pharma AB (Sweden)
- Reddy’s Laboratories Ltd (India)
- Medimetriks Pharmaceuticals, Inc. (US)
- Merz Pharma (Germany)
- Kaken Pharmaceutical Co., Ltd (Japan)
- Johnson & Johnson Services, Inc. (US)
- GlaxoSmithKline plc (UK)
- Taro Pharmaceuticals Industries Ltd (Israel)